Detalhe da pesquisa
1.
Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
Int J Cancer
; 152(5): 921-931, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36161271
2.
Early Locoregional Breast Surgery and Survival in de novo Metastatic Breast Cancer in the Multicenter National ESME Cohort.
Ann Surg
; 277(1): e153-e161, 2023 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33534229
3.
Pattern and risk factors of isolated local relapse among women with hormone receptor-positive and HER2-negative breast cancer and lymph node involvement: 10-year follow-up analysis of the PACS 01 and PACS 04 trials.
Breast Cancer Res Treat
; 199(2): 371-379, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36988749
4.
Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.
N Engl J Med
; 381(26): 2506-2518, 2019 12 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-31566937
5.
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancer.
Breast Cancer Res Treat
; 191(1): 191-207, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34687411
6.
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Lancet Oncol
; 21(11): 1513-1525, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32926841
7.
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME program.
Int J Cancer
; 145(12): 3359-3369, 2019 12 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-31087564
8.
Sarcomas in patients over 90: Natural history and treatment-A nationwide study over 6 years.
Int J Cancer
; 145(8): 2135-2143, 2019 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30924137
9.
Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens.
Breast Cancer Res Treat
; 173(2): 397-406, 2019 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-30357526
10.
Survival Impact of Locoregional Treatment of the Primary Tumor in De Novo Metastatic Breast Cancers in a Large Multicentric Cohort Study: A Propensity Score-Matched Analysis.
Ann Surg Oncol
; 26(2): 356-365, 2019 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-30539492
11.
Biosimilar filgrastim treatment patterns and prevention of febrile neutropenia: a prospective multicentre study in France in patients with solid tumours (the ZOHé study).
BMC Cancer
; 18(1): 1127, 2018 Nov 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30445935
12.
A prospective observational study on the evaluation of everolimus-related adverse events in metastatic renal cell carcinoma after first-line anti-vascular endothelial growth factor therapy: the AFINITE study in France.
Support Care Cancer
; 25(7): 2055-2062, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28188447
13.
Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
Lancet Oncol
; 17(5): 600-11, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-27032301
14.
The New Combination Docetaxel, Prednisone and Curcumin in Patients with Castration-Resistant Prostate Cancer: A Pilot Phase II Study.
Oncology
; 90(2): 69-78, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26771576
15.
Is it important to adapt neoadjuvant chemotherapy to the visible clinical response? An open randomized phase II study comparing response-guided and standard treatments in HER2-negative operable breast cancer.
Oncologist
; 20(3): 243-4, 2015 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-25637380
16.
Clinical benefits of non-taxane chemotherapies in unselected patients with symptomatic metastatic castration-resistant prostate cancer after docetaxel: the GETUG-P02 study.
BJU Int
; 115(1): 65-73, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24180479
17.
Personalised chemotherapy based on tumour marker decline in poor prognosis germ-cell tumours (GETUG 13): a phase 3, multicentre, randomised trial.
Lancet Oncol
; 15(13): 1442-1450, 2014 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-25456363
18.
Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Lancet Oncol
; 14(2): 149-58, 2013 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-23306100
19.
A Randomized, Open-label, Cross-over Phase 2 Trial of Darolutamide and Enzalutamide in Men with Asymptomatic or Mildly Symptomatic Metastatic Castrate-resistant Prostate Cancer: Patient Preference and Cognitive Function in ODENZA.
Eur Urol
; 85(3): 274-282, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37271630
20.
Clinical outcome of patients with isolated central nervous system progression on first-line pertuzumab and trastuzumab treatment for HER2-positive metastatic breast cancer in a real-life cohort.
Breast Cancer
; 30(2): 329-341, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-36630013